The iShares Biotechnology ETF (NASDAQ:IBB – Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders purchased 36,759 put options on the company. This represents an increase of about 479% compared to the average daily volume of 6,354 put options.
Institutional trading with iShares Biotechnology ETF
A number of institutional investors have recently made changes to their positions in IBB. International Assets Investment Management LLC acquired a new position in iShares Biotechnology ETF during the 4th quarter valued at $563,000. Tennessee Valley Asset Management Partners acquired a new position in shares of iShares Biotechnology ETF during the 4th quarter valued at about $44,000. abrdn plc acquired a new position in shares of iShares Biotechnology ETF during the 4th quarter valued at about $5,928,000. Signaturefd LLC increased its holdings in shares of iShares Biotechnology ETF by 14.2% during the 4th quarter. Signaturefd LLC now owns 1,120 shares of the financial services provider’s stock valued at $152,000 after purchasing an additional 139 shares during the last quarter. Finally, Klingenstein Fields & Co. LP acquired a new position in shares of iShares Biotechnology ETF during the 4th quarter valued at about $216,000. Institutional investors and hedge funds own 62.45% of the company’s shares.
Price development of the iShares Biotechnology ETF
iShares Biotechnology ETF stock opened at $147.38 on Wednesday. iShares Biotechnology ETF has a 1-year low of $111.83 and a 1-year high of $150.17. The company has a 50-day moving average price of $141.56 and a 200-day moving average price of $136.94.
About iShares Biotechnology ETF
(Get free report)
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index includes securities of NASDAQ-listed companies that are classified as either biotechnology or pharmaceuticals according to the Industry Classification Benchmark and also meet other eligibility criteria established by NASDAQ.
Selected articles
Get daily news and reviews on the iShares Biotechnology ETF – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iShares Biotechnology ETF and related companies with MarketBeat.com’s FREE daily email newsletter.
